United States · Bill · HR
H.R. 1902 (110th)
Protecting Consumer Access to Generic Drugs Act of 2007
Introduced
17 April 2007
Last action
4 May 2007 · Referred
Status
Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
Sponsors
Rep. Rush, Bobby L. [D-IL-1], Rep. Waxman, Henry A. [D-CA-33], Sen. Markey, Edward J. [D-MA], Rep. Butterfield, G. K. [D-NC-1], Rep. Doyle, Michael F. [D-PA-14], Rep. Schakowsky, Janice D. [D-IL-9], Rep. Dingell, John D. [D-MI-12], Rep. Marshall, Jim [D-GA-8], Rep. Gordon, Bart [D-TN-6], Rep. Gonzalez, Charles A. [D-TX-20], Rep. DeGette, Diana [D-CO-1], Rep. Stupak, Bart [D-MI-1], Rep. Wynn, Albert Russell [D-MD-4], Sen. Van Hollen, Chris [D-MD]
Subjects
Healthcare
Source updated
14 August 2025
Summary
Protecting Consumer Access to Generic Drugs Act of 2007 - Prohibits, as an unfair and deceptive act or practice and an unfair method of competition in or affecting interstate commerce, any person from being a party to any agreement resolving or settling a patent infringement claim in which: (1) an abbreviated new drug (generic) application filer receives anything of value; and (2) such filer agrees not to research, develop, manufacture, market or sell the generic drug. Excludes a resolution or settlement that includes no more than: (1) the right to market the generic drug before the expiration of the patent or other exclusivity period; or (2) the waiver of a patent infringement claim for damages. Authorizes the Federal Trade Commission (FTC) to exempt agreements in furtherance of market competition and for the benefit of consumers. Amends the Federal Food, Drug, and Cosmetic Act to provide that a generic drug applicant forfeits market exclusivity for failing to market the drug 75 days after: (1) a court dismisses a declaratory judgment action for lack of subject matter jurisdiction; or (2) the applicant files with the Secretary of Health and Human Services a covenant that the patent owner will not sue the applicant for patent infringement. Deems an applicant to have forfeited market exclusivity if the applicant enters into an agreement that violates this Act. Amends the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to revise reporting requirements related to agreements between a generic drug applicant and a brand name drug company to include: (1) a description of the subject matter of other agreements between the parties; and (2) a certification that the materials filed represent the complete, final, and exclusive agreement between the parties.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
17 April 2007
Introduced
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
17 April 2007
Introduced
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
17 April 2007
Introduced
Introduced in House
Source: IntroReferral
17 April 2007
Introduced
Introduced in House
Source: IntroReferral
18 April 2007
Referred
Referred to the Subcommittee on Commerce, Trade and Consumer Protection.
Source: Committee
2 May 2007
Committee
Subcommittee Hearings Held.
Source: Committee
4 May 2007
Referred
Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 17 April 2007 · Download file
Documents
3 official files
Introduced in House (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House (text)
Introduced in House · EN · 17 April 2007
Introduced in House (PDF)
Introduced in House · EN · 17 April 2007
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 17 April 2007
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. Rush, Bobby L. [D-IL-1] · D · Sponsor
- Rep. Waxman, Henry A. [D-CA-33] · D · Sponsor
- Sen. Markey, Edward J. [D-MA] · D · Sponsor
- Rep. Butterfield, G. K. [D-NC-1] · D · Sponsor
- Rep. Doyle, Michael F. [D-PA-14] · D · Sponsor
- Rep. Schakowsky, Janice D. [D-IL-9] · D · Sponsor
- Rep. Dingell, John D. [D-MI-12] · D · Sponsor
- Rep. Marshall, Jim [D-GA-8] · D · Cosponsor
- Rep. Gordon, Bart [D-TN-6] · D · Cosponsor
- Rep. Gonzalez, Charles A. [D-TX-20] · D · Cosponsor
- Rep. DeGette, Diana [D-CO-1] · D · Cosponsor
- Rep. Stupak, Bart [D-MI-1] · D · Cosponsor
- Rep. Wynn, Albert Russell [D-MD-4] · D · Cosponsor
- Sen. Van Hollen, Chris [D-MD] · D · Cosponsor
- · hsju00 · Standing
- · hsif00 · Standing
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/110th-congress/house-bill/1902
- Open data entity: https://api.congress.gov/v3/bill/110/hr/1902
- us · 110-hr-1902 · source updated 14 August 2025